The impact of low-frequency genetic variation on metabolic traits of blood serum by Nzau, Makenzi
The impact of low-frequency genetic
variation on metabolic traits of blood
serum
Makenzi Nzau
School of Science
Thesis submitted for examination for the degree of Master of
Science in Technology.
Espoo 6.6.2019
Thesis supervisor:
Prof. Jari Saramäki
Thesis advisors:
Prof. Samuli Ripatti
D.Sc. (Tech.) Taru Tukiainen
aalto university
school of science
abstract of the
master’s thesis
Author: Makenzi Nzau
Title: The impact of low-frequency genetic variation on metabolic traits of
blood serum
Date: 6.6.2019 Language: English Number of pages: 5+63
Life Science Technologies
Professorship: Jari Saramäki
Supervisor: Prof. Jari Saramäki
Advisors: Prof. Samuli Ripatti, D.Sc. (Tech.) Taru Tukiainen
The effect of genetic variation on the small-molecule (metabolite) composition blood
serum has hitherto been investigated with regard to common genetic variation
(CV) or very-rare(Mendelian) genetic variation. However, the effect of intermediate,
low-frequency variation remains less characterized.
This Thesis investigates the hypothesis, that low-frequency variation within the
coding region of metabolic genes induces extreme metabolite accumulation or
depletion on carrier individuals with respect to the population mean.
The sample population consists of 1159 general population individuals from the
Finnish population with blood metabolite content quantified using high-performance
liquid-chromatography in conjunction with mass-spectrometry.
This hypothesis is tested on selected candidate metabolites and candidate genes.
The set of metabolites was obtained from prior literature of Mendelian metabolic
disease, whereas the candidate genes originate from two sources. The first set
originates from the mentioned disease literature, and the second set is obtained by
analysis CV study results.
The population distribution of these metabolites is segregated into three groups:
positive–, negative–tail and center. According to the hypothesis, the tail-groups
contain an excess of carriers of above-mentioned low-frequency variation. The
results of the suggest association, but not at desired significance level.
Keywords: metabolism,metabolomics,genetics,genomics, outlier, inborn errors of
metabolism, loss-of-function, RVAS
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Preface
The physiological state of an individual depends on a myriad of environmental
factors. Examples of such factors include socioeconomic status, lifestyle choices
and life-events (i.e. , history of illnesses, pregnancy). Thus, the environmental
factors which shape the individual may vary vastly across individuals and time.
However, genetic constitution remains invariant with respect to time and these
factors. Consequently, genetic constitution provides for a plausible point of reference
in the effort to tailor medical treatment to suit individual. Conversely, the state of
metabolism (chemical balance within the individual) can be thought to capture an
instantaneous snapshot of the individual as a biological totality.
The pursuit of the bridging of the gap between these two approaches holds great
promise; to generate novel perspective on therapeutic practices and ultimately to
our understanding of life as phenomenon.
From the authors perpective, the purpose of this Thesis is to investigate a
particular approach to this task, hopefully contributing to the foundation of advances
yet to come. Otaniemi, 6.6.2019
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11 Introduction
The prior genome-wide association studies (GWAS) have been used to identify genetic
variants affecting common diseases on the population scale. However, these studies
have focus on common genetic variation (population frequency ≥ 5%). In contrast,
linkage analysis has uncovered numerous causal variants of rare inherited disease
in families of susceptible pedigree [1]. The exceedingly low-frequency ( 1%) of
these so called Mendelian diseases render them virtually absent from population-scale
random samples [2]; these diseases are detected mainly through the clinic due to
their extreme and early onset symptoms.
The intermediate frequency range (between 5% and 1%) of low-frequency genetic
variation remains less investigated. The aim of this Thesis is to characterize the
impact of low-frequency variation on human metabolic traits on population scale. The
traits investigated in this Thesis are small-molecule (metabolite) concentrations in
blood serum. The hypothesis presented in this work relies on the following postulates:
• Common variation results in small to moderate impact on metabolic traits,
whereas Mendelian variation results in extreme impact (inborn error of metabolism
(IEM)) –– thus low-frequency variation might result in an intermediate impact
between the two.
• IEM-variants induce loss-of-function (LOF) on genes facilitating metabolism
–– thus this Thesis examines low-frequency variants with potential to impact
the function of particular genes. That is, variants in coding region (exome) of
the genome.
• The causal LOF of the IEM results in cascade failure of metabolism. These
failures lead to select metabolite depletion or accumulation involved key metabo-
lites –– thus the carriers of low-frequency variants might be expected to present
depletion or accumulation of select metabolites.
In this Thesis, the measurement set of metabolite concentration constitute a
sampling distribution. The impact of genetic variation manifests in the properties
of these distributions. To accomodate this fact, the above mentioned postulates
coalesce into the following qualitative hypothesis: the three regimes of genetic
variation transform the distribution distinctly. The impact of common variation
shifts the mean of the total distribution, whereas the impact of Mendelian variation
induces bimodality onto the total distribution.
As the intermediate, this Thesis proposes as its hypothesis that low-frequency
variation inflates the tails of the total distribution, as illustrated in Figure 1. More
succinctly: low-frequency genetic variation within the coding region in select can-
didate genes should be enriched in subjects lying in the tail of selected metabolite
concentration distribution. The set of candidate genes are selected by two sources :
directly from prior IEM annotations and indirectly from a previous common variation
association study [3].
2Figure 1: The qualitative contrast between typical variant carrier and non-carrier
serum metabolite concentration distributions. Common variation refers to variants
with frequency > 5%, ultra-rare Mendelian variants with frequency  1% and
low-frequency variants with 1%− 5%. Common variation typically induces a shift in
mean, Mendelian variation bimodality and according to our hypothesis, low-frequency
variation expand the tail region.
3Figure 2: Coarse-grained diagram of data-flow. Features consist of candidate genes
and metabolites. Metabolites are chosen based on IEM gene-metabolite pairs. The
chosen metabolites are used to select candidate genes based on metabolic genome-
wide association study (mGWAS) variants and IEM annotation from the KEGG [4]
annotation service.
Metabolic data KEGG annotations;
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2 Background
2.1 Structure and function of the genome
The human genome consists of 23 pairs distinct units of DNA called chromosomes.
These chromosomes can be further divided into two categories: the autosomal and
sex chromosomes. Autosomal and sex chromosomes differ by the obligatory count
inherited by a healthy individual. Figure 3 illustrates the typical female and male
chromosome sets.
Each individual chromosome consists of two strands of deoxyribonucleic acid
(DNA). In turn, each strand consists of an ordered sequence of four nucleotides:
adenosine (A), thymine (T), guanine (G), cytosine (C). Each strand is paired with a
complement strand, in which each nucleotide in replaced by their complement. A is
the complement of T and vice versa, and conversely G and C are complementary.
Briefly stated, each strand is coded in a quatenary code of four bases and possess
a redundant complement strand. Figure 4 shows how the strand coils to form
chromosomes.
The genome contains the necessary information to synthesize and regulate the syn-
thesis of protein molecules in the cell. This information is contained in regions called
genes. Approximately 1.1% of the genome consists of protein-encoding sequences and
4% key regulatory sequences and other vital non-coding sequences [5]. These protein
4Figure 3: Overview of genome structure on chromosome level. The human genome
consists of 44 autosomal and two sex chromosome. A: A normal male chromosome
set stained for optical microscopy. The male chromosome set contains one of both
X and Y chromosomes. B: a normal female chromosome set stained for optical
microscopy. The female chromosome set contains two X chromosomes. This figure
is a composite of Figures 5.2 and 5.3 (pg.59 , pg.60) of [5]. Modified and reprinted
from "Essential Medical Genetics", by Tobias, Edward S. and Connor, Michael and
Ferguson-Smith, Malcolm ; Copyright (2011) John Wiley & Sons.
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5Figure 4: The composition of a chromosome in terms of DNA strand. Within the
chromosome, the DNA-strand coils recursively in to the elementary fiber, which in
turn is coiled into the chromatin fiber. Finally, the chromatin fiber is coiled into the
chromosomal chromatid visible in the staining of 3. This figure is based on Figure 5.1
(pg.58) of [5]. Modified and reprinted from "Essential Medical Genetics", by Tobias,
Edward S. and Connor, Michael and Ferguson-Smith, Malcolm ; Copyright (2011)
John Wiley & Sons.
6Figure 5: The protein molecules organize cell structure and metabolism. These
properties enable or prevent the cell from organizing into tissues or other structures.
In this figure, glucose transporter-4 and the insulin receptor organize and regulate
glucose transport across cell membrane. Via wikimedia commons XcepticZP; public
domain
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7act as the basic components of information and matter flow pathways between cells
and cell compartments. As an example, Figure 5 illustrates the transport of glucose
across the cell membrane to downstream chemical processes.
The function and properties of a single protein molecule is dictated by it’s primary
structure. From a chemical standpoint, proteins are chains of amino acids called
polypeptides. These polypeptides are an ordered sequence of twenty possible amino
acids. The sequence determines the three-dimesional structure which the polypeptide
folds into. This three-dimensional structure in turn determines the biochemical
function of the protein. Some protein consist of multiple folded chains linked by
post-translational modification. Figure 6 illustrates these levels of structure via a
protein called PCNA.
Figure 7 illustrates the process of information flow from the DNA strand into the
synthesis of polypeptide chains. The process of deriving protein polypeptide chain
from the information provided by the strand sequence is described by the central
dogma of molecular biology. Briefly, the dogma dictates that the information of the
DNA-molecule is transcribed into a single-stranded nucleotide sequence molecule
called ribonucleic acid (RNA). Three of the nucleotides are identical; the fourth,
called uracil (U), replaces thymine (T). Next, this raw transcript undergoes a process
of editing called splicing. During splicing sections called introns are removed. The
remaining sections (called exons) constitute the template for the polypeptide chain.
This messenger RNA (mRNA) is then parsed in nucleotide triplets called codons.
Each codons denotes the start of the translation, a specific amino acid or the end of
translation. [5]
A gene is the region of the genome, which contains the necessary information for
the transcription of a protein. Fundamentaly, genes can be divided to two subregions:
regulatory and coding regions. Regulatory regions interact with the mechanisms
regulating transcription rate. For example, these regions can serve as binding sites for
other protein which promote or suppress transcription of the encoded protein. These
regions can lie adjacent to the regulated coding region (cis-regulation) or distant to
it (trans-regulation). The coding region contains the exons and the introns. [5]
2.2 Inheritance
Inheritance is the transmission of traits from parent to offspring. The genome
mediates this process by storing the necessary information.
8Figure 6: The protein contains three or four levels of structure. The first level
(primary structure) is the amino acid residue sequence. The secondary structure
is the local of folding of local section of the protein. The tertiary structure is the
global folding of the protein. The fourth is the intertwining and ligation of separate
polypeptide strands. The illustrated protein is PCNA. Via Wikimedia Commons by
Thomas Schafee (Evolution and evolvability); cc BY-4.0 license; [6]
9Figure 7: The production process of protein polypeptide chain from genetic DNA
information. The DNA sequence is transcribed into mRNA; the primary mRNA
is purged of introns, leaving only concatenated exon sequences. The final mRNA
is translated into the polypeptide chain. Modified and reprinted from "Essential
Medical Genetics", by Tobias, Edward S. and Connor, Michael and Ferguson-Smith,
Malcolm ; Copyright (2011) John Wiley & Sons.
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Figure 8: Mendelian inheritance with diploid organisms: 1. Definition of diploidy:
each individual carries two copies of chromosomes. The blue chromosomes confer the
blue phenotype and the red chromosomes the red phenotype; 2. The formation of
sex-cells entails fission of the diploid genome into single-copy haploid genomes; 3. As
result of mating or crossing, the haploid sex-cells fuse resulting in diploid offspring;
4. Dominant and recessive trait: the red trait dominates the blue, recessive trait.
That is, all red-blue heterozygotes present the red trait. Via Wikimedia Commons
(modified) Asychterz18;(CC BY-SA 4.0 license); [7]
4
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Figure 9: The principle of homologous recombination: The maternal (M) and paternal
(F) chromosomes recombine by exchanging sections. The result is twohaploid genomes
of two sex-cells. Via wikimedia commons David Eccles (Gringer); cc-by-2.5 license [8]
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Figure 10: Origin of linkage and LD. Linkage within a family: linkage is the result of approximate conservation of crossover sites.
T. Typical segment (or haplotype) lengths are large enough to conserve linkage over few generations. This results in correlation
between alleles which share haplotype; LD within a population: Linkage can observed on population scale. Alleles correlate
over significant distances. However, due to randomness in recombination, the correlations decay over generations leading to an
uncorrelated equilibrium. Thus, linkage disequilibrium tends towards linkage equilibrium. Figure by William S. Bush, Jason H.
Moore via Wikimedia commons; cc-by-3 license [9]
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Even though the detailed molecular basis of inheritance is complex, it can be
conceptualized using two events: the transmission of the genome and the development
of traits from said genome.
The individual obtains one chromosome per chromosome pair from each parent.
This chromosomes is derived via recombination of the respective parents corresponding
chromosome pair. Thus each parent contributes a recombined half-genome (haploid)
to the offspring (figure 8).
The generation of haploid genomes from diploid genomes is called meiosis. During
meiosis, the parental chromosomes pair by chromosome type. Then, the both
chromosomes exchange segments by process called homologous recombination as
illustrated in Figure 9. Finally, the recombined chromosomes segregate, forming two
types haploid genomes.
The form of this process leads to two noteworthy consequences. First, only
one allele can be inherited from two ancestral alleles of the parent. Second, the
randomness inherent to the selection of end and start loci of recombined segments
implies decoupling of loci within the ancestral chromosome. The decoupling has been
observed between chromosomally distant locus , but with lower frequency between
adjacent locus. This phenomenon is called chromosomal linkage (CL) and it results
in correlation between alleles in adjacent loci. This phenomenon vanishes in on
population scale on the long-term, but population bottlenecks can sustain linkage
between alleles. This phenomenon is called LD and it has profound implications
on population genetics. Figure 10 illustrates the origin and evolution of LD across
generations in the population.
The development of traits from the genome depends on the examined trait.
The most elementary (or Mendelian) traits vary due to variation in individual loci.
That is, hetero- or homozygosity with respect to the causal locus determines the
presented trait. Figure 8 illustrates an example of this. However, common diseases
such as coronary artery disease (CAD) or type 2 diabetes (T2D) or continuously
quantitative traits (height, BMI) are not accurately explained by the Mendelian
mode of inheritance. In contrast to Mendelian traits, these traits are often influenced
by the environment and depend on a myriad of loci.
The most elementary model used for these traits is an additive model within
and between loci. That is, each allele affects the trait independently and the sum of
effects totals the genetic variance of the trait.
3 Genetic variation
The genetic sequence varies from individual to individual. This variance may lead
in individual differences in traits such as height or disease risk [10, 11]. These
variations are either inherited (the mixing properties of meiosis) or produced de novo
by DNA damaging agents (UV radiation, mutagenic chemicals) or by errors in DNA
replication. [5]
Genetic variation can be categorized in several ways: by structure, effect or
frequency in the population of interest. Structure-wise, variants can be divided
14
Figure 11: Illustration of multiple types of length mutation at chromosome scale.
Via wikimedia commons ;public domain
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into two categories: point mutations (or single nucleotide polymorphism (SNP))
and length mutations. Point mutations involve a substitution of a single nucleotide,
whereas variants resulting in insertions or deletions are called length mutations [5].
Insertions or deletions can range from length of several nucleotides to entire sections
of the chromosome (chromosomal translocation). Figure 11 illustrates the spectrum
of length mutations discussed above on the scale of the chromosome. In the scope of
this Thesis, all variants considered are SNPs. In this case, the functional impact of
a variant depends on the site of the variant. Specifically, whether the variant lies
within a protein-coding or a regulatory region of a gene.
At the most elementary, variants substitute a codon for another. If a substitution
of synonymous codons occurs, the sequence remains unaltered. These variants are
called silent mutations. Variants causing non-synonymous substitutions are called
missense mutation. variant resulting in premature stop-codons are called non-sense
mutation [12]. More complex alterations can be caused by splice-site mutations.
Splice-site mutationsare variants on the intro-exon boundary, which alter splicing
process. This can lead to inclusion of entire introns or exclusion of exons.
Thus in principles, exonic variants may impact the host protein significantly. Non-
sense mutations either produce truncated or no protein.Missense mutations in turn
may produce protein, but with typically reduced or no activity. The consequences of
splice-site mutations are more diverse, and hence constitute an independent class [13].
The typical consequence of these mutations is LOF in the host protein. However,
gain-of-function mutations have been observed as well [5]
Most common variants impact the individual at best moderately. Exceptions
have been discovered, such as several variants harboured by the APOE gene, which
significantly increase the risk of late-onset Alzheimer’s disease in European popu-
lations [14]. By contrast, known rare variants are likely harm to individual. For
example, causal variants of cystic fibrosis are SNP which are rare among the general
population but enriched in affected families. Other examples of such variants underlie
Crohn’s and Huntington’s disease [15].
Genetic variation has been studied primarily on two scales: family and population.
Family-scale studies investigate the effect of variation by comparing trait variation
between and within sets of related individuals, whereas in population-scale studies
examine general effects independent of descent. Family-scale studies have discovered
the genetic basis of a myriad of rare inheritable diseases, but fail to explain the
heritability of common diseases. This observation serves as the basis of tthe common-
disease-common-variant hypothesis. This hypothesis states that single high-impact
variants explain rare disease risk, whereas multiple minor or moderate impact variants
explain common disease risk. Given the large number and minute impact of the sought
variants, large sample sizes are necessary for statistical power. Thus, population-scale
studies arise as solution.
3.1 Genome Wide Association Study
The effect of common variation on a phenotype within a population is investigated
by means of genome-wide association study. The common variation consists of
16
selected single nucleotide polymorphism loci; the population is then sampled for
a representative sample. Then, the these sampled individuals are genotyped and
measured for the chosen phenotype. The task of GWAS is to determine for each
locus, whether carriers of similar alleles agree by phenotype.
Two aspects define the statistical framework of GWAS: the study design and
genotype model. Study design depends largely on the phenotype. Dichotomous
phenotypes can be examined with a case-control design, while continuous traits are
typically examined quantitatively. The genotype model dictates the grouping of
genotype. For example, a two-allele (major allele A, minor a) dominant model groups
the genotypes aA,AA,Aa together and AA as the other group. [15]
The typical quantitative trait locus analysis (QTL) study has a continuous
phenotype with an allelic additive model. The allelic additive model groups genotypes
by allele count. For a two allele locus, the classes are 0,1,2 copies of the minor allele.
Each copy is assumed affect the quantitative phenotype identically. The effect can be
statistically measured and tested with generalized linear models such as ANOVA [15].
4 Metabolism
Metabolism refers to regulated transformation and transport of chemical species
(metabolites) within the body or across its boundaries. Metabolites are typically
transformed in chemical reactions catalyzed by protein called enzymes. Most reactions
are catalyzed by a single, specific enzyme, which without the reaction would not
proceed. Thus, the activity and the concentration of the key enzyme regulates the
balance between the substrate and the product concentrations.
These reactions can assemble into linear, cyclic or branching sequences called
pathways. These pathways are typically separated by physical compartments. These
compartments can be cellular organelles such mitochondrion or tissues. Transporter
protein transport chemical species across the barriers between these compartments.
Transporters may function uni- or bidirectionally and vary in specificity.
In the context of this Thesis, all metabolites are small-molecules, as opposed
to large macromolecules such as protein peptide chains. Figure 12 demonstrates
phenylalanine metabolism. The reaction from phenylalanine to tyrosine is catalyzed
by the enzyme phenylalaninehydroxylase (PAH). The disruption of the gene encoding
for PAH leads to the IEM phenylketonuria (PKU) [45].
4.1 Metabolomics
Metabolomics is the high-throughput study of small-molecule compounds and their
biochemistry in biofluid or tissue. Measurements may provide up to hundreds of
small-molecule metabolites concentrations simultaneously. These metabolites can be
endogenous compounds such as amino acids, carbohydrates, nucleotides or lipids or
exogenous compounds such as pharmaceuticals, food additives or pesticides. Thus,
metabolomic methods are ideal for measuring the state of complete biochemical
substructures, such as metabolic pathways [16].
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Figure 12: Amino acid metabolism responsible for the IEM phenylketonuria (PKU).
The key metabolites phenylalanine and tyrosine are obtained through dietary intake
and amino acid recycling. They further transform into metabolites downstream. The
enzyme phenylalaninehydroxylase (PAH) catalyzes the conversion of its substrate
(phenylalanine) to the product, tyrosine. Disruption of this conversion results in
PKU. Several Mendelian variants are known to induce LOF on PAH. Figure 1 of
Williams, R. A., Mamotte, C. D., & Burnett, J. R. (2008); Copyright (2005) The
Australasian Association of Clinical Biochemists Inc.
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Spectroscopic techniques provide the foundation for metabolomic methods. The
two most popular families of techniques are mass spectrometry (MS) and hydrogen
nuclear magnetic resonance (H-NMR), detect compounds in atto- and micromolar
resolution respectively [17]. Since analysis require little biofluid or tissue, these
techniques scale to epidemiological sample sizes. Additionally, techniques from both
families can be used to quantify previously unknown metabolites. Metabolomic
studies which also quantify unknown metabolites are called untargeted studies.
Conversely, Metabolomic studies with a priori chosen metabolites of interest are
called targeted studies.
Although the two families share numerous attributes, they differ in several key as-
pects. Briefly, H-NMR-based analyses involve minimal sample handling, are generally
non-destructive and produce easily quantifiable results. These benefits come at the
cost of specificity and sensitivity. Namely, the lower spectral resolution of H-NMR
based techniques leads to reduced distiguishability between similar compounds. Like-
wise, the sensitivity to compound quantity is orders of magnitude lower than that of
MS-based. Conversely, MS-based techniques gain sensitivity and precision at the cost
of introducing complexity into the analysis. Factors, such as compound ionizability
and ion suppression, must be accounted for gain precision. Furthermore, MS-based
analyses often feature chromatographic separation prior to spectral measurement.
This increases peak separability but at the risk of introducing nuisance factors [17].
There are numerous biofluids and tissues of interest. Typically studied biofluids
include blood, saliva and urine but even cerebrospinal fluid has been used [18]. The
primarily metabolomic studies have focused on blood and urine. This is due to the
fact that these fluids represent the global state of metabolism.
5 Genomic analysis of metabolomic phenotypes
The above mentioned techniques enable metabolomic studies with thousands of
samples, rendering association studies to genetic variation feasible on epidemiolog-
ical scale. As all descriptions of physiological processes are in theory metabolic,
metabolomics does not impose strict boundary condition to study structure. Instead,
the phenomenon of interest and it’s genetic architecture provide the boundaries for
study structure. As a result, the variety of developments in study structure and
composition have taken place.
Three aspects outline the dimensions of development: increase in study population
size and diversity, increase in genotyping depth and increase in phenotype structure
depth. Initial studies had relatively low sample size sampled from a single cohort,
genotyped with low resolution and little or no structure in metabolic phenotype. The
subsequent studies have developed with respect to one or more of these aspects.
5.1 Cohort size and diversity
The first studies were genome-wide association study on measurements of metabolite
content of blood. The study structure standard QTL mapping, hence the term
19
metabolic quantitative locus (mQTL) for alleles influencing metabolite content [19,
20, 21].
Gieger et al. [19] noted that using concentration ratios instead of individual
concentration values produced a sharp increase in significance (p-value) of discovered
associations. The proposed interpretation for the phenomenon is that a certain subset
of these ratios represent the substrate-product equilibrium in enzymatic reactions
(substrate-product relation illustrated in Figure 12). Gieger et al. [19] present variants
discovered on the FADS1 and LIPC genes. Similar studies have been performed with
larger sample-sizes and numerous cohorts [22, 3, 23]
5.2 Phenotype structure depth
Prior biochemical or clinical knowledge can be exploited in a myriad of ways. The
subsequent mGWAS-derived studies vary in their approaches to exploitation. These
approaches can be laid on a spectrum of supervisedness. Supervised approaches
impose specific a priori biochemical pathway or clinical onto the metabolite or
genotype data. In contrast, unsupervised are impose an abstract, general structure
upon the data (e.g. pathway or gene-gene interaction network).
In the study conducted Hartiala et al. [24], the role of a specific biochemical
pathways in CAD risk is investigated. Hartiala et al. investigate the effect of betaine
metabolism on CAD risk mediated by choline metabolism. Specifically, the study
focused on two competing pathways of choline metabolism: the TMA pathway and
the betaine pathway. The activity of these pathways have been implicated in an
increase and reduction of CAD risk respectively. Based on this premise, they first
performed a genome-wide association study on plasma betaine levels. The discoveries
comprised the set of variants of interest. This set was then tested for association
with metabolites of interest; that is, a subset of the intermediate metabolites of the
betaine pathway. Finally, the immediate and metabolite-mediated difference in CVD
risk was evaluated and compared for each variant.
In the unsupervised end of the spectrum lies the mGWAS by Mittelstrass et al. [25].
Instead of leveraging a priori pathway knowledge, they construct a gaussian graphical
machine (GGM) onto the set of metabolites. This GGM models the correlation
structure of these metabolites as graph with metabolites as nodes and significant
correlations as edges. The GGM then provides a context which in sexual dimorphisms
in serum metabolite content and subsequent sex-stratified mGWAS results are
analyzed. Specifically, effect of sex on serum metabolite concentration was quantified
with linear regression. The inferred regression coefficients placed on the GGM network
as vertex weights. Then, the community structure of connected, similarly weighted
vertices were analyzed. GGM-based approaches have been extended and applied in
other contexts [26].
5.3 Genotype resolution depth
Advances in genotyping resolution has been leveraged by mGWAS-based studies.
Particulary exome sequencing has been used in metabolic genetic association stud-
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ies [27, 28, 29, 30]. Exome sequencing provides two key advantages to general
genome-wide association study: power to detect rare variation and context for dis-
covered variants. Since exomes are gene-encoding regions, the relevance of discovered
variants can be more readily evaluated. On the functional level, the change in enzyme
or transporter activity can be readily interpreted in clinical or experimental settings.
On the structural level, the impact of variant can be evaluated by its consequence
on the produced polypeptide chain.
Yu et al. investigate the effect of variants predicted to cause LOF in the host gene.
Such variants were defined as SNPs and small indels resulting in truncated protein
or non-viable transcripts. More specifically, they selected variants causing premature
stop-codons, frameshift or splice-site disruption. Then, they quantified variant effect
by regressing metabolite levels on allele count par with standard mQTL analysis.
6 Inborn errors of metabolism
IEM are defined as inherited metabolic diseases caused by ultra-rare (frequency in
population  %1) variants. The hallmark of these diseases is extreme accumulation
or depletion of signature metabolites.
As with other Mendelian diseases, due to their extremely low-frequency, these
diseases have been typically studied in families enriched with the causative variants.
[1]
Currently, there are numerous known IEM with diverse clinical and biochemical
manifestation. Thus multiple types of taxonomy have been formulated. Given the
molecular focus of this Thesis, the following taxonomy presented by Salmi et al. [31]
fits this Thesis well.
IEM are typically caused by the LOF of enzymes or enzyme co-factors facilitat-
ing biochemical reactions, or metabolite transport protein between compartments
(illustrated in 12). The impact of the LOF on the target reaction and pathway can
thus be described followingly,
1. Accumulation of enzyme substrate,
2. Depletion of enzyme product,
3. Accumulation of typically minor metabolites,
4. Secondary metabolic consequences ,e.g, acidosis or ketosis.
The first two features result directly from failure of the target reaction, whereas the
latter can be ascribed to systemic disruption of metabolism on pathway scale. The
first three impacts generate the signature mentioned above.
The prior research of IEM therefore shows that these signature metabolites can
exhibit extreme variation caused by genetic variation. Thus, the set of signature
metabolitesconstitute an ideal candidate set of metabolites. Furthermore, the causal
genes constitute plausible set of candidate genes.
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The annotation service KEGG [4] provided IEM annotations for this Thesis.
These annotations map IEM genes to associated metabolites.
The dataset contains 9 IEM metabolites corresponding to 9 IEM 3. Furthermore,
these annotations provide a list of candidate genes per IEM 4.
7 Methods and materials
7.1 SNP causality - candidate genes
In addition to the IEM gene-set, this Thesis also considers genes implicated by the
prior mGWAS of Shin et al. [3].
Establishing the mechanism of a mGWAS discovered SNP on the trait of interest
requires two steps. First, the discovered SNP may present a false positive discovery
due to LD (see Subsection 2.2). That is, the discovered variant might occur merely
in correlation with the true causative variant [32]. These tag SNPs can be filtered
using LD-pruning. The process of LD-pruning examines the strand in windowed
segments. These windows are centered around each candidate variant and are fixed
length-wise. Windows containing many candidate variants are likely to contain
only one causal single nucleotide polymorphism and multiple tag single nucleotide
polymorphisms. The most significantly associated variant is selected by p-value as
the causal single nucleotide polymorphism and the remaining are discarded. These
causal single nucleotide polymorphism serve as genetic landmarks to identify the
structure of the pathways or mechanism of interest.
To establish the mechanism of effect, the causal SNP is mapped onto set of
plausibly affected genes. Genes located near causal single nucleotide polymorphisms
map onto the candidate set. The simplest mapping is windowed selection of nearby
genes. However, this task is untrivial as many discovered SNPs lie in intergenic
regions. In other words, the shortest distance from single nucleotide polymorphism
to gene can be extremely large and vary vastly from genetic region to region. This
can somewhat accounted for by appropriately large window-size. [33]
A large window in the dense region of the genome results in disproportionate
variation in the number of candidate genes per single nucleotide polymorphism.
Limiting the number of candidate genes selected per single nucleotide polymorphism
evens the proportions.
In this Thesis, the mGWAS discoveries of Shin et al. [34] for the selected candidate
metabolites provide the candidate single nucleotide polymorphism set. The following
process selects the mGWAS candidate gene-set per metabolite.
Preprocessing: Prior to LD-pruning, all discoveries with p ≥ 10−5 were discarded.
LD-pruning: The set of remaining discoveries were LD-pruned with window-length
of 500kb1 resulting in a set of causal single nucleotide polymorphisms
Gene selection: For each causal single nucleotide polymorphism, genes within the
15kb window were selected.
1kb short for kilobase
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Gene count normalization: Finally, the ten closest genes to each window center
(that is, causal single nucleotide polymorphism) were selected to the final set.
7.2 Rare variant analysis and extreme phenotype sampling
Rare variant analysis presents a challenge to the statistical methods used in common
variant association studies: the lack of statistical power. This challenge can be
mitigated by increased sample sizes or large effect sizes of discovered variants. However,
an alternative to these measures is using specialized statistical methods and study
designs [35].
This Thesis adapts two methods from the above mentioned publication: extreme
phenotype sampling (EPS) and region-based testing.
The first method adapted into this Thesis is EPS. EPS involves sampling the tails
of the phenotype distribution. Typically this distribution is assumed or deliberately
transformed to normal distribution. As a result, definition of the tail region becomes
intuitively and rigorously defined. This definition will be further explored in ??.
Region-based test aggregate adjacent variants into a combined region. The region-
based hypothesizes, that this region comprises a functional unit. Therefore, the
number of minor alleles carried by an individual in this region determines their
phenotype. In other words, the individual effects are compounded into a single
quantity. The effect of this total quantity is then tested for association with the
phenotype. In the context of this Thesis, these regions are candidate genes. As
mentioned before, this Thesis aims to investigate plausible LOF variants in candidate
genes. Consequently, this leads to two criteria for variant selection:
• The variant site should lie within or near an exon and preferably encode a
non-synonymous mutation mutation.
• The variants should present a minor allele frequency (MAF) less than or equal
to 5% in the finnish population according ExAc
Given the division of samples into tail and center groups and the aggregation of
variants into compound regions, the objective of this Thesis can be formulated as
follows: to detect enrichment in the number mutant alleles by region within the tail
groups in contrast to the center group. Lee et al. list multiple methods designed to
achieve this task.
This Thesis employs the following design: Instead of compounding the muta-
tional burden over individuals, it is compounded over the group. That is, the total
frequency of minor alleles within a tail population against the central population.
The association is tested with the χ2 test.
The χ2-test measures the association between two categorical variables. The do-
main of both variables consist of independent and mutually exclusive categories. Thus
an association between two variables is measured by the number cross-occurrences
between categories of these variables. McHugh et al. have elaborated this method
further in their 2013 publication [36]. The population variable consists of three
mutually exclusive categories: positive–tail, negative–tail and inlier. The genotype
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variable per metabolite per gene consists of two categories: carrier and non-carrier.
The mGWAS and IEM gene-sets are tested independently of each other.
Formulated in terms of χ2 quantities: we wish to test whether the observed
count of variants in either tail O+, O− differ significantly from the expected count
E[+], E[−]. The expected count is derived from the frequency of carriers in the inlier
population. These are compared via the test statistic Q+, Q−.
Stated in terms of null– and alternative, we have the following hypotheses:
Null-hypothesis (1) p+ = pinlier,
Null-hypothesis (2) p− = pinlier,
Alternative hypothesis: p+ 6= pinlier or p− 6= pinlier.
Here, p± refers to the proportion of variants in the positive (or negative) tail
group and pinlier to the proportion of carriers within inlier group.
In terms of the test statistic Qi,±, according to the null-hypothesis we have
Qi,± ∼ χ2((r − 1)(c − 1)), where χ2 is the χ2 distribution and r, c the degrees
of freedom. These degrees of freedom refer to the number of categories for the
variables. In the study design of this Thesis, each tail is compared to the inlier
population separately. This implies that r = 2 is the number of categories on the
metabolite distribution (positive tail, inlier; negative tail, inlier). Each gene is tested
independently; each gene contains two two-categories: carrier and non-carrier. Thus
for each candidate gene i, we have the following quantities,
Ei[+] = n+fi,
Ei[−] = n−fi,
Qi,+ = (Oi,+ − Ei[+])2/Ei[+],
Qi,− = (Oi,− − Ei[−])2/Ei[−].
Above, fi is the frequency of variant carriers within the inlier population, n+, n−
are the sizes of the tail populations and Qi,+, Qi,− are the test quantities measuring
association.
7.3 Metabolic variation and outliers
The state of metabolism varies between individuals as well as within individuals
over time. Numerous factors may explain this variation: genetic, environmental and
developmental factors have been investigated [37, 38]. Typically, extreme observations
or outliers have been discarded or ignored in these studies. However, it is known
that IEM result in extreme metabolite levels in tissue or biofluid. This shows that
genetic variation might explain some of these discarded outliers. The robustness of
these outliers observations presents a challenge. By definition, outliers are observed
sparsely, so biological or measurement noise may explain their occurence.
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There are several statistical definitions of outliers [39]. In this Thesis, outliers
are defined as observations in the tail of the univariate Gaussian distribution. Given
standardized metabolite concentrations z, outliers zoutlier are defined as:
z ∼ N(0, 1) (1)
|zoutlier| ≥ zc (2)
zc > 0 is the threshold of extremity.
This definition can be applied sensibly if the distributions examined are unimodal
and symmetric. The larger the deviation from these conditions, the less motivated
this definition is. Figure 13 shows an example of this.
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Figure 13: Outlier threshold marked on three distributions. The sensibility of this
definition varies: A. The distribution, which is symmetric and unimodal. Outliers
are sensible and well-defined. B. The distribution is unsymmetric. The tails are
unequal in size, thus a common threshold is questionable. C. The distribution is
bimodal and skewed. The outliers are ill-defined.
0 0
0
A. B.
C.
-zc -zc
-zc zc
zczc
Inlier
outlier
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Figure 14: QQ-plot of IEM metabolites against the standardized normal distribution
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QQ-plots can be used to characterize the properties of distributions in parameter-
free manner. The QQ-plot compares the number of observations per quantile between
a reference distribution and an empirical distribution. In Figure 14, the IEM
metabolite distributions have been plotted against the standard normal distribution.
Notably, all metabolite distributions conform to the reference distribution within
the central quantiles z ∈ [−2, 2]. However, the tails are markably skewed and each
distribution exhibits different rates of deviation from the reference distribution. This
implies that optimally zc would be chosen individually per distribution per tail.
However, this might introduce comparability issues between metabolites. Based on
these observations and Figure 14, a reasonable range for a common zc would lie in
the interval [2, 3].
The choice of zc presents a potential trade-off; lower zc provides higher sample
size, but may in principle lower the power of the employed test [40]. Testing the
effect of zc on power is method dependent and therefore out of the scope of this
Thesis. Therefore zc = 2 remains as the natural choice.
7.4 Cohorts
The study subjects were sampled from two cohorts: COROGENE and Predict-CVD
cohorts. The COROGENE-study cohort consists of case and control subjects from
the acute coronary syndrome [11]; however only control subjects were selected for
the study of this Thesis. This Thesis. These subjects participated in the FINRISK
07 survey [41] The subjects The Predict-CVD cohort consists of case and control
subjects from a prospective cardiovascular disease (CVD) study of Vartiainen et
al. [41]. All participated in the FINRISK survey of 97.
Table 1: Summary statistics of the subjects from the COROGENE cohort
- male female total
N 278 236 514
mean BMI( kg
m2 ) 27.0± 3.8 26.7± 5.4 26.8± 4.7
mean age(a) 52.6± 13.6 50.8± 13.9 51.6± 13.8
Table 2: Summary statistics of the subjects from the PredictCVD cohort
- male female total
N 404 231 635
mean BMI( kg
m2 ) 27.5± 3.9 26.3± 4.4 27.0± 4.1
mean age(a) 50.7± 13.8 51.0± 13.3 50.9± 13.6
7.5 Metabolite measurement
The subjects were asked to fast for four hours prior to blood sampling. The blood
was extracted from a vein in the antecubital fossa. Then, the sampled blood was
kept for 30 min at room temperature and centrifuged for 11 min. at 2200g using a
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Hettich Rotofix 32 centrifuge. Finally, the plasma and the serum were aliquoted and
frozen either with dry ice or to -20 degC using a freezer. Whole blood samples used
for DNA extraction were freezed in the latter manner.
Sample preparation was conducted as described Evans et al. [42] by Metabolon,
Inc.
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Figure 15: Metabolites with more than 50% and known name divided into eight superpathways and 62 subpathways. The area
enclosed by each box in proportional to the fraction of metabolites in the pathway.
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In total, 647 metabolites were reliably identified with 281 previously unknown.
These metabolites can be classified into eight categories: amino acids, carbohydrates,
cofactors & vitamins, energy metabolites, lipids, nucleotides, peptides and xenobiotics.
These superpathways are further subdivided to 62 subpathways.
Metabolites were selected based on number of missing values. Metabolites with
more than 50% missing values were discarded. Figure15 summarizes the set of
metabolites selected in preprocessing.
7.6 Genotype measurement
The COROGENE cohort was genotyped using Illumina 670k array and the Pre-
dictCVD using Illumina 710k. Imputation;
Due to the complex ramifications of sex chromosome inheritance, only variants
in autosomal chromosomes shall be studied in this Thesis. Chosen variants fulfilled
three conditions : possessing MAF ≤ 5 according to Exome aggregation consortium
(EXAC), lying in the coding region of a gene of interest and predicted by VEP (see
next Subsection) to impact the resulting protein moderately or highly. In total X
variants fulfilled these conditions. See appendix for additional information. Genotype
data was processed using plink (v.1.90) and QCTOOL.Individuals with haplotype
confidence for a variant less than 90% were declared missing with respect to said
variant.
Genes of interest consist of two sets: those associated with IEM, and those implied
by existing mGWAS-hits from Shin.et al. [34].
The KEGG-database [4] provided the IEM gene-metabolite pairs.
7.7 Statistical analysis and annotation resources
The bulk of statistical computation was performed in python 3.5.2 using Pandas
package (version 0.18.1) and Scipy (version 0.17.1) on Mac (version OSX 10.5.6).
Metabolite levels were log transformed and thereafter standardized. The trans-
formed measurements were then corrected for age, sex, BMI, cohort membership and
fast length via linear regression using the package scikit-learn (v.0.17.1). VEP was
used to predict variant effect. KEGG (Release 89.0+/03-22) [4] was used to choose
IEM metabolites as well as the associated genes. The database was accessed using
the Bioservices (v. 1.5.2) python package. All genomic distance were computed
using pybedtools (v. 0.7.5) and Ensembl (GRCh37.74).
8 Results
The study design employed by this Thesis subdivides into two phases: Preprocessing
and feature selection, and enrichment testing. Summarily, the first stage consists
of selecting metabolites and candidate genes of interest. Next, distributions of
selected metabolites are subdivided into inlier-outlier groups and candidate genes are
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Figure 16: The detailed flow of the study design.
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examined for low-frequency variants of interest. The detailed flow of data selection
and preprocessing are outlined in Figure 8.
The enrichment testing in turn consists of comparing combined frequencies of
variants per gene-region between outlier and inlier groups. Outlier groups consist of
the positive and negative tail of the distribution and the inlier group the remaining
center. The enrichment was tested using the standard χ2 test comparing total variant
frequency per gene of the inlier against both outlier groups.
8.1 Candidate genes
The IEM of interest were chosen based on two condition: first, they must be linked
in KEGG to metabolites within the sample and second, their causative gene must lie
within a autosomal chromosome.
As previously explained, we chose metabolites exhibiting extreme variation (|z| >
2). The number of these metabolites is 9. However, one metabolite (serotonin (5HT))
was associated with a gene in the X chromosome and thus was excluded from analysis.
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Table 3: KEGG IEM with metabolites present in sample
name KEGG ID linked metabolite Type OMIM
H00165 Tyrosinemia H00165 tyrosine Organic acidaemia 276700 276600 276710 140350
H00167 Phenylketonuria; H00167 phenylalanine Organic acidaemia 261600 261630 233910 261640 264070
H00171 Histidinemia H00171 histidine Organic acidaemia 235800
H00172 Maple syrup urine disease H00172 leucine Organic acidaemia 248600 246900 615135
H00184 Hypermethioninemia H00184 methionine Organic acidaemia 250850 180960 606664 614300
H00186 Hyperargininemia H00186 arginine Organic acidaemia 207800
H00188 Hyperlysinemia H00188 lysine Organic acidaemia 238700
H00190 Hyperprolinemia H00190 proline Organic acidaemia 239500 239510
H00469 Mitochondrial DNAdepletion syndrome H00469 pyruvate Mitochondrial disease
603041 609560 251880 203700
613662 612073 256810 271245
612075 245400 221350 615084
615418 615471 617156
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Table 4: IEM associated autosomal genes
Gene names
Histidinemia HAL
Hyperargininemia ARG1
Hyperlysinemia AASS
Hypermethioninemia MAT1A,AHCY,GNMT,ADK
Hyperprolinemia PRODH2,ALDH4A1
Maple syrup urine disease BCKDHA,BCKDHB,DBT,DLD,PPM1K
Mitochondrial DNA depletion syndrome
TYMP,TK2,DGUOK,MDP1,SUCLA2
,MPV17,C10orf2,RRM2B,SUCLG1
,AGK,MGME1,SLC25A4,FBXL4,TFAM
Phenylketonuria; PAH,QDPR,GCH1,PTS,PCBD1
Tyrosinemia FAH,TAT,HPD
Table 5: The summary of IEM candidate genes: each is metabolite paired with
corresponding causal IEM genes.
gene names
histidine HAL
leucine BCKDHA,BCKDHB,DBT,DLD,PPM1K
phenylalanine PAH,QDPR,GCH1,PTS,PCBD1
tyrosine FAH,TAT,HPD
lysine AASS
methionine MAT1A,AHCY,GNMT,ADK
arginine ARG1
proline PRODH,ALDH4A1
pyruvate TYMP,TK2,DGUOK,MDP1,SUCLA2,MPV17,C10orf2,RRM2B...
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Tables 3 and 4 diplay the chosen IEM and their causal genes. The metabolite
are finally paired with corresponding IEM genes in 5
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distance (bp) gene name
metabolite SNP
arginine rs511304 2555 NAALADL2
rs6479442 5706 FGD3
rs6059244 9842 DEFB121
rs2781668 495,1843 ARG1,MED23
rs2293683 0,9194,10107,14263 FARSA,SYCE2,CALR,GCDH
rs12985777 430,1429,6575 JSRP1,OAZ1,C19orf35
rs12714263 2493 CLIP4
rs12061159 5173 RGS21
rs7036499 8998,14259 SLC25A25,NAIF1
rs837763 2110 PIEZO1
histidine rs715 0 CPS1
rs7014133 1085 ADCY8
rs1527683 3124,3124 FPGT-TNNI3K,TNNI3K
rs3733588 0 SLC2A9
lysine rs10165613 1706 SCN9A
rs10491431 120 UGT3A1
rs12268257 2865 GPR158
rs12927959 7364 GFOD2
rs1364344 12483 SMPD3
rs1402325 427,4391,5449,5634,8548 ZNF576,SRRM5,IRGQ,ZNF428,L34079.2
rs1714369 5711 INSC
rs3024547 781 IL4R
rs6587731 2379,10084 PRR9,LELP1
rs7583413 345 C2orf83
rs1179979 2765 SLC25A21
methionine rs11925382 83 DNAJC13
rs17478241 1474 ARHGAP5
rs3740996 0,9637 TRIM5,TRIM22
rs4693555 1823 COPS4
rs6008770 0,8420 TRMU,CELSR1
rs6533609 4719 ALPK1
rs2066415 14534 KIAA2026
phenylalanine rs1565225 218 RALYL
rs2953014 1013 NF1
rs937475 191 PAH
rs10050054 2604 RP11-389E17.1
proline rs893175 8009 CBLN1
rs7187836 10976 C16orf47
rs715544 1408,2483,13471 DGCR14,GSC2,TSSK2
rs6798346 12759 PPP4R2
rs2935623 12048,14587 C5orf38,IRX2
rs175866 1264 MTHFD1L
rs10512634 1000 UGT3A1
rs10197940 12478 RIF1
rs7560860 5588 EML4
pyruvate rs1133034 1192 ATP11B
rs11259923 3849 ADAMTSL3
rs10770353 5090,11184 PIK3C2G,RERGL
rs7751620 14517 MCHR2
rs4648464 11228 PRDM16
tyrosine rs10033622 2605 SORBS2
rs936632 3108 FAM159A
rs906466 11416 DLGAP4
rs8057124 9496 IST1
rs7834337 10032 ERICH1
rs7151615 2055 TTC5
rs4808739 10288 IL12RB1
rs12891 0 CERS4
rs11243929 1167,8576 TSC1,C9orf9
rs10516469 6642,7683 PPP3CA,AP001816.1
rs10500559 375 PHLPP2
rs11625663 299,2508 SNW1,SLIRP
Table 6: The selected mGWAS-variants which provided candidate genes and those
genes. For brevity, the variants and candidate genes of the metabolite leucine are
listed in Appendix A.
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The mGWAS-candidate genes were selected based on Shin et al. [3] results. The
published SNP-list was thresholded with p ≤ 10−5 and LD-pruned over a 500kb
window as described in 7.1.
Finally, each selected variant produced candidate genes listed in ??. Genes were
selected from within a 15kb window centered around each chosen variant. At most
ten genes were chosen per window. The pruning and threshold parameters were
chosen to produce a comparable number of candidate genes to the IEM candidate
genes. The selected mGWAS variants and the associated genes are listed in 8.1.
8.2 Selected variants
Chosen variants for both candidate gene sets were chosen based on two criteria,
• If the any minor alleles satisfy MAF ≤ 5% in according to ExAc estimated
frequency in finnish population.
• If the variant lies within the coding region (i.e, VEP annotated “BIOTYPE” is
“protein_coding” )
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Table 7: The number of low-frequency variants selected per IEM candidate gene.
num.variants
metabolite gene
arginine ARG1 3
Total 3
phenylalanine GCH1 3
PAH 11
PCBD1 1
PTS 5
QDPR 6
Total 26
pyruvate AGK 3
C10orf2 14
DGUOK 18
FBXL4 14
MDP1 5
MGME1 8
MPV17 12
OPA1 22
RRM2B 5
SLC25A4 4
SUCLA2 4
SUCLG1 21
TFAM 12
TK2 11
TYMP 11
Total 164
proline ALDH4A1 20
PRODH 25
Total 45
histidine HAL 16
Total 16
methionine ADK 18
AHCY 10
GNMT 6
MAT1A 12
Total 46
leucine BCKDHA 10
BCKDHB 9
DBT 8
DLD 6
PPM1K 3
Total 36
lysine AASS 15
Total 15
tyrosine FAH 10
HPD 8
TAT 5
Total 23
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Table 8: The number of low-frequency variants selected per mGWAS candidate gene.
The number of variants chosen for leucine candidate genes are listed in Appendix A.
num.variants
metabolite gene
arginine ARG1 6
C19orf35 49
CALR 28
CLIP4 16
DEFB121 1
FARSA 70
FGD3 51
GCDH 35
JSRP1 28
MED23 28
NAALADL2 16
NAIF1 6
OAZ1 49
PIEZO1 106
RGS21 3
SLC25A25 45
SYCE2 56
Total 593
phenylalanine NF1 28
PAH 11
RALYL 7
Total 46
pyruvate ADAMTSL3 23
ATP11B 12
MCHR2 4
PIK3C2G 60
PRDM16 39
RERGL 4
Total 142
proline C16orf47 12
C5orf38 15
CBLN1 2
DGCR14 63
EML4 32
IRX2 18
MTHFD1L 14
PPP4R2 7
RIF1 54
TSSK2 9
UGT3A1 30
Total 256
histidine ADCY8 18
CPS1 33
FPGT-TNNI3K 58
SLC2A9 12
Total 121
methionine ALPK1 48
ARHGAP5 9
CELSR1 154
COPS4 12
DNAJC13 41
KIAA2026 27
TRIM22 22
TRIM5 20
TRMU 18
Total 351
lysine C2orf83 6
GFOD2 3
GPR158 11
IL4R 57
INSC 18
IRGQ 15
PRR9 2
SCN9A 58
SLC25A21 10
SMPD3 45
SRRM5 50
UGT3A1 10
ZNF428 15
Total 300
tyrosine C9orf9 6
CERS4 20
DLGAP4 13
ERICH1 7
FAM159A 3
IL12RB1 36
IST1 12
PHLPP2 30
PPP3CA 12
SLIRP 6
SNW1 30
SORBS2 72
TSC1 28
TTC5 21
Total 296
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The number of variants varied by metabolite and gene. Table 7 summarizes this
information for IEM and Table 8for mGWAS.
8.3 Enrichment analysis
The complete outline of the performed test is provided by RVAS section 7.2. Briefly,
the enrichment test examines the equality of the proportion of variant carrier per
tail group (p+, p−) against the proportion in the inlier population (pinlier). More
concisely,
Null-hypothesis(1) p+ = pinlier,
Null-hypothesis(2) p− = pinlier,
Alternative hypothesis: p+ 6= pinlier or p− 6= pinlier.
Both tails are tested independently. Within the two comparison, each gene
constitutes an indepent test. The number of test varies between metabolites and
hence the multiple testing corrected p-value threshold varies as well. The correction
here used here is the Bonferroni correction.
gene counts Bonferroni p-value
metabolite
phenylalanine 4 0.012500
arginine 17 0.002941
proline 12 0.004167
tyrosine 15 0.003333
lysine 16 0.003125
methionine 9 0.005556
pyruvate 6 0.008333
histidine 5 0.010000
leucine 114 0.000439
Table 9: The number of IEM-genes per metabolite. The number of genes corresponds
to the number of χ2 tests performed per metabolite. To account for multiple tests,
the nominal p-value p = 0.05 is divided by the number of tests.
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gene counts Bonferroni p-value
metabolite
phenylalanine 4 0.012500
arginine 17 0.002941
proline 12 0.004167
tyrosine 15 0.003333
lysine 16 0.003125
methionine 9 0.005556
pyruvate 6 0.008333
histidine 5 0.010000
leucine 114 0.000439
Table 10: The number of mGWAS-genes per metabolite. The number of genes
corresponds to the number of χ2 tests performed per metabolite. To account for
multiple tests, the nominal p-value p = 0.05 is divided by the number of tests.
The results of the association test are displayed in abbreviated form in this section.
For the positive tail z > 2, the results are contained in Table 13 for the IEM variants
and mGWAS variants 14. The respective negative tail results are contained in Table
11 and Table 14.
The Tables 8.3 and 8.3 list the Bonferroni corrected p-value thresholds per
metabolite. The IEM-results are not significant at the nominal threshold p ≤ 0.05.
The mGWAS-results contain nominally significant results, but none are significant
after Bonferroni correction. In the wider context, the results do not support the
exact hypothesis, that coding variant are not enriched within the tail subpopulations.
This in turn does not support the qualitative hypothesis regarding the intermediate
Table 11: Top ten associations of IEM candidate gene variants from negative tail(z <
−2). There are no nominally significant (p ≤ 0.05) tests. The number of observed
carriers in the negative tail is indicated by n− and the number of expected carriers is
indicated by E[n−]. The p-value of the χ2 test for enrichment is indicated by p(−)
n− E[n−] ninlier Q(-) p(-) metabolite num. variants
PRODH 5.0 5.501799 322.0 0.045767 0.169400 proline 25
QDPR 1.0 0.801259 27.0 0.049295 0.175705 phenylalanine 6
MAT1A 1.0 1.262590 52.0 0.054613 0.184777 methionine 6
HPD 3.0 3.525180 112.0 0.078241 0.220305 tyrosine 8
PCBD1 0.0 0.089029 3.0 0.089029 0.234584 phenylalanine 1
AGK 0.0 0.107914 4.0 0.107914 0.257468 pyruvate 3
FBXL4 3.0 2.428058 90.0 0.134724 0.286417 pyruvate 14
PAH 1.0 1.454137 49.0 0.141830 0.293531 phenylalanine 11
PTS 2.0 1.513489 51.0 0.156389 0.307497 phenylalanine 5
SLC25A4 5.0 4.127698 153.0 0.184343 0.332333 pyruvate 4
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Table 12: Top ten associations of mGWAS candidate gene variants from negative
tail (z < −2). The number of observed carriers in the negative tail is indicated by
n− and the number of expected carriers is indicated by E[n−]. The p-value of the χ2
test for enrichment is indicated by p(−)
n− E[n−] ninlier Q(-) p(-) metabolite num. variants
SRRM4 8.0 7.884892 274.0 0.001680 0.032698 leucine 14
CELF4 4.0 3.856115 134.0 0.005369 0.058411 leucine 10
IRGQ 1.0 1.079137 40.0 0.005803 0.060724 lysine 3
NRG3 3.0 2.848921 99.0 0.008012 0.071322 leucine 10
SLC25A25 2.0 2.135791 95.0 0.008633 0.074030 arginine 15
CERS4 1.0 1.101619 35.0 0.009374 0.077129 tyrosine 10
TRNT1 3.0 2.820144 98.0 0.011470 0.085290 leucine 10
FGD3 6.0 6.272482 279.0 0.011837 0.086637 arginine 17
IRF2 4.0 3.769784 131.0 0.014059 0.094384 leucine 11
COPS4 5.0 5.317446 219.0 0.018951 0.109494 methionine 6
Table 13: Top ten associations of IEM candidate gene variants from positive tail(z >
2). There are no nominally significant (p ≤ 0.05) tests. The number of observed
carriers in the positive tail is indicated by n+ and the number of expected carriers is
indicated by E[n+]. The p-value of the χ2 test for enrichment is indicated by p(+)
n+ E[n+] ninlier Q(+) p(+) metabolite num. variants
HAL 2.0 2.179856 101.0 0.014840 0.096957 histidine 16
ADK 1.0 0.836331 31.0 0.032030 0.142038 methionine 8
PTS 1.0 0.825540 51.0 0.036869 0.152267 phenylalanine 5
PAH 1.0 0.793165 49.0 0.053936 0.183650 phenylalanine 11
DLD 1.0 1.282374 62.0 0.062178 0.196914 leucine 6
AGK 0.0 0.071942 4.0 0.071942 0.211471 pyruvate 3
DGUOK 2.0 2.428058 135.0 0.075465 0.216460 pyruvate 6
AASS 1.0 1.456835 90.0 0.143254 0.294933 lysine 15
ALDH4A1 13.0 14.511691 489.0 0.157474 0.308507 proline 19
BCKDHA 2.0 1.509892 73.0 0.159088 0.310002 leucine 10
43
Table 14: Top ten associations of mGWAS candidate gene variants from positive
tail(z > 2). The number of observed carriers in the positive tail is indicated by n+
and the number of expected carriers is indicated by E[n+]. The p-value of the χ2
test for enrichment is indicated by p(+)
n+ E[n+] ninlier Q(+) p(+) metabolite num. variants
PHACTR2 4.0 4.012590 194.0 0.000040 0.005015 leucine 12
SDHD 1.0 1.013489 49.0 0.000180 0.010691 leucine 5
ADAM12 4.0 4.053957 196.0 0.000718 0.021379 leucine 20
TSC22D2 2.0 1.902878 92.0 0.004957 0.056130 leucine 11
RIN3 1.0 1.075540 52.0 0.005305 0.058065 leucine 10
CERS4 1.0 0.912770 35.0 0.008336 0.072748 tyrosine 10
FAM149A 2.0 2.151079 104.0 0.010611 0.082044 leucine 13
VAX2 1.0 1.116906 54.0 0.012237 0.088082 leucine 5
MAP2K6 1.0 1.116906 54.0 0.012237 0.088082 leucine 7
SNW1 1.0 1.121403 43.0 0.013143 0.091272 tyrosine 10
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impact of low-frequency genetic variation stated earlier in the Section 1.
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9 Discussion
The results do not support to the hypothesis of intermediate impact. More concisely,
the hypothesis whereby low-frequency genetic variation constitutes a novel regime of
impact on metabolic traits besides the known regimes of common and Mendelian
variation. This outcome is possible through two scenarios: either the impact remains
undetected in this Thesis or low-frequency does not constitute an independent regime
by impact.
Both scenarios can be analyzed via four fields illustrated in Figure17. The
division of the Thesis’ study into metabolic and genomic aspects is self-evident;
however the division into sampling and feature selection aspects warrants further
elaboration. Features refer to the set of relevant variables. Selecting candidate genes
reduces the number of variables comprising the genotype. Analogously, selection and
transformation of metabolite distributions define the relevant metabolic phenotypes.
9.1 Genotype sampling aspect–– study design and associa-
tion testing
The most direct factor influencing detection is the choice of statistical test. The
intrinsic properties of the χ2 test either boost or dampen its power in a given
experimental design. Most likely, the defining property of the χ2-test is its non-
robustness to low number of expected observations in any group. The heuristic
threshold of minimum group size is 5 samples [36]. Simple modifications to test
this assumption would be to select candidate genes with more plausible LOF low-
frequency variants leading to higher carrier count on expectation. However, it is
unclear whether this leads to bias and to which direction.
The usage of the test in the Thesis’ design presents an additional confounding
factor. Namely, that it assumes coding variants have a similar impact in direction
and magnitude. This could be potentially ameliorated by modifying the study design
by stratifying the variants by expected impact size or direction. The expected impact
Figure 17: A fourfold division of the study of this Thesis. On the level of theory, the
Thesis involves two domains: metabolic and genomic. On the level of study design or
experiment, the two domains are feature and sampling. The feature domain dictates
what is being observed. The sampling domain dictates what are observations. Their
intersections comprise four distinct aspects of the Thesis study.
Genetic Metabolic
Sample
Feature Candidate gene Metabolite distribution
genotype outlier
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could be estimated from mutation type (missense mutation,non-sense mutation) or
minor allele frequency. Then each strata would constitute an independent χ2 test.
An other option would involve choosing an alternative test. Lee et al. report a
number of rare-variant tests, which account for some of these heterogeneities [35].
Some of these test may simultaneously correct for the impact of common variation
as well [44] and can be adapted through weighting-schemes.
9.2 Genetic feature aspect–– gene selection
The choice of IEM candidate genes was largely dictated by available annotation
resources. The KEGG [4] database provided both IEM genes and metabolites.
Grouped according to the criterion presented by Salmi et al. [31] (see also section 6),
the IEMs provided by KEGG are all organic acidemias. This might incur a selection
bias.
The choice of mGWAS candidate genes provides for degrees of freedom. The
choice of single nucleotide polymorphism threshold p-values, pruning distances, gene-
window length and maximum number of genes chosen from the window affect the
number and chromosomal distribution of candidate genes significantly. The current
choice of parameters normalizes the number of mGWAS candidate genes to match
the number of IEM genes. Curiously, the the two candidate gene sets have only one
common gene: PAH.
This observation raises a crucial question: to what extent is it a consequence of
the sets’ origins (mGWAS, IEM)? The above mentioned parameter-choice issue and
the statistical nature of mGWAS-results might inject noise to the process.
Brodie et al. [33] have investigated the effect of gene window length when associ-
ating mGWAS-variants to causative genes. Using a method presented in the article,
they discovered that not only did optimal length vary by phenotype, but that for some
single nucleotide polymorphism the length was exceedingly long (500kb compared to
this Thesis’ 10kb). This method linked each single nucleotide polymorphism to a
pathway and discovered a set plausible candidate gene by distance.
This method of generating candidate gene from single nucleotide polymorphisms
eliminates the four parameters and provides additional context for the selected
genes. Thus, it is more robust without foreseeably reducing the benefits of using
mGWAS-variants.
The gene function and structure might affect its susceptibility to LOF. This
dimension could be accounted for by studying existing IEM genes and the impact of
variation on their chemical activity. Blau et al. [45] have studied the causal gene,
PAH, of the IEM phenylketonuria.
9.3 Metabolic sampling aspect–– outlier definition
Canonically, outliers are interpreted as observations not generated by the process of
interest. In a carefully constructed, controlled experiment, typically only one process
is of interest; the rest comprise measurement noise. Thus samples conforming to
expected tendencies of this process can be justifiably selected and non-conforming
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outlier samples discarded. However, when outliers are generated by the process of
interest, this distinction is inapplicable. This raises the question: how to distinguish
extreme observations attributable to relevant processes from those attributable to
noise? Concretely this issue manifests itself in this Thesis in the choice of outlier
thresholds. While a high threshold dampens measurement noise, it reduces sample
size.
The assumed type of the distributions impacts the choice critically. An elementary
example is attributing observations from a fat-tailed distribution to a thin-tailed
distribution. More concretely, if the observations are generated by a Student-t
distribution, then assuming a normal distribution leads to a significant number of
outliers. Since the Thesis dataset contains a range of skewed and kurtotic distributions
which persist even after log-transformation, this issue is relevant to the the results.
Furthermore, the literature on expected distribution type and shape is lacking.
One notable phenomenon regarding extreme observations in high-dimensional
data, is the curse of dimensionality. The curse of dimensionality refers to mul-
tiple linked phenomena; however, the phenomenon of data-snooping bias applies
acutely [46]. The data-snooping bias states that given any individual sample, the
probability of this individual being an outlier increases as the number of dimensions
increases. As the number of tested metabolite distributions increases, the probability
of sampling an individual who is not an outlier with respect any metabolite drastically
drops. The bias affects unsupervised (model-free) outlier detection. Thus in principle,
the bias could be mitigated or at least accounted for by explicitly assuming a model.
Thus, a statistical framework to quantify the number of expected outlier and their
magnitude is needed. Such a framework could rely on domain agnostic methods such
as extreme-value analysis [47] or biological models such as the Gaussian graphical
machines studied by Krumsiek et al. [48].
Additionally, other mathematical formulations of outliers than the distribution
based might prove more robust to these phenomena [39], though extensive work must
done to ascertain this.
Furthermore, the measurement process of metabolite levels might affect dis-
tributions as well. Differences of detection thresholds might introduce spurious
outliers. Specifically, this applies to metabolites with significant numbers of missing
observations, since missingness can be attributed to concentrations below detection
threshold.
As mentioned before, many of the metabolite distribution are kurtic. Since kurtosis
refers to the tendency of the distribution to produce outliers [49], analytic sources of
it undermines the biological relevance of outliers. This could be investigated through
studying whether mass-spectrometric or chromatographic attributes of compounds
predict kurtosis significantly.
9.4 Metabolic sampling aspect-– biological validation
The metabolic state of an individual varies across time. The scale of this variation
is subject to the physiological and clinical state of the individual. For example,
individuals diagnosed with organic acidemias display serum amino acid contents
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orders of magnitude higher from the healthy population.
In the context of this Thesis, outliers are extreme observations with respect to the
sampled population. Thus, in principle they might lie well within range of clinical or
biological reference levels.
The biochemical validation could be done through comparisons with in silico
models. Nijhout et al. [50] have shown in silico that the chemical reaction networks
of at least certain metabolic pathways are capable of buffering against perturbation
innately. They due so partly by virtue of their network structure and by active
regulation of reaction fluxes. In the context of the Thesis, their key insight is that
this buffering effect mitigates perturbations regardless of origin; that is, external
or internal. Thus a loss-of-function in an enzyme or transporter protein might not
result in extreme perturbation of individual metabolites, but moderate perturbation
of entire metabolic processes. This might thus manifest as a lack of univariate-
Gaussian outliers despite biological relevance. This motivates the investigation of
the joint-distribution of metabolites –– of multidimensional outliers [39].
Contrarily, given the non-essential nature of some metabolites, extreme variation
in these metabolites might prove irrelevant.
Thus, the context provided by these models could be used for selection of relevant
metabolites or provide for a framework for combining raw metabolites into composite
features. Developing and validating such complex models is beyond the scope of
this Thesis or any immediate work. However, such models have been published.
Cvitanovic et al. [51] have published a review on genome scale dynamic models of
liver metabolism.
From a clinical perspective, the model for organic acidoses proposes an empirical
alternative. Salmi et al. [31] present a decomposition of the metabolic consequences of
aminoacidemias (see also ??). Especially secondary metabolic consequences (clinically
significant systemic perturbations such as ketosis) might provided a clinical validation
of outlying metabolite concentration.
10 Conclusions
This Thesis has studied the impact of low-frequency coding genetic variation on
serum metabolite composition in a Finnish sample of the general population. The
genes studied for coding-variation were obtained from prior literature (IEM), as well
as empirically from mGWAS results. The candidate metabolites were obtained from
IEM-literature. According to the hypothesis presented, the carriers of these variants
should be enriched in the tail population of metabolite distributions. Although the
results of this Thesis do not confirm the hypothesis, it serves as proof-of-concept
for a systemic approach towards the intersection of the clinical, biochemical and
statistical life-sciences.
By integrating further clinical insight from IEM, of biochemical pathway knowledge
and statistical theory of outliers, the hypothesis presented can be examined from
new angles. These ingredients are readily available. However, it is unclear as to
which of these directions should occupy the central role in the future. Answering
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this question is a matter of interdisciplinary deliberation.
50
A Leucine genes and variants
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Table 15: The selected mGWAS variants and the consequent candidate genes for
leucine.
distance (bp) gene name
SNP
rs37959 4940,6035 RPA3-AS1,GLCCI1
rs3906146 302 LMX1B
rs4073959 615 MTL5
rs4074961 2516 RSPO1
rs3775574 0 IRF2
rs2933284 12464 SLC6A1
rs4681618 4788 TSC22D2
rs440752 5145 REG3G
rs4432749 1379 TBC1D14
rs4593819 0,568 CASP9,DNAJC16
rs2898645 12806 SEPT9
rs4693209 781 PPM1K
rs4758270 1711 TUB
rs4077470 6485 NTF3
rs2454043 2091 ATP6V1C1
rs2722276 528 EPDR1
rs17265788 1391 CES5A
rs1818106 3454,5622 DDI1,PDGFD
rs1822834 12098 ALDH1A2
rs1881909 9906 CPNE4
rs192689 137 NMNAT3
rs1971105 419 EML6
rs211167 4575 FHL5
rs2146498 9482 RIN3
rs2273875 239 TARBP1
rs2275977 388,5000 DERL3,SMARCB1
rs2285137 0,10290 POLDIP3,SERHL2
rs2302423 0 CCDC179
rs4767788 3242 SRRM4
rs2478832 1577 KIAA1462
rs2634945 1201 DDX60L
rs2819318 10229 NOS1AP
rs477992 2793 PHGDH
rs606798 3596 CELF4
rs481781 107 PRKCI
rs7584842 496 GREB1
rs7622687 9577,10424 DNASE1L3,FLNB
rs769630 476 SUMF1
rs7707382 5602 ANKRD33B
rs7912957 2661 ATE1
rs7915 0,1164,6810 ZFYVE19,PPP1R14D,DNAJC17
rs797348 1546 EGLN3
rs7996613 3059 MYO16
rs8131355 4732 SH3BGR
rs849327 12095 JAZF1
rs885561 3949 LIPA
rs891878 8338 MYT1L
rs9403527 14360 PHACTR2
rs9521172 5384 MYO16
rs9840386 4148 FGF12
rs989960 2057 SLC26A3
rs7584322 7267 VAX2
rs757378 2943,13485 RAB11FIP4,NF1
rs4889294 4 BCMO1
rs4920094 186,5665 TFF1,TMPRSS3
rs4957023 6690,7055 AHRR,PDCD6
rs4968791 8043 MAP2K6
rs4978780 1562 EPB41L4B
rs618001 13709 PICALM
rs6441140 7349 C3orf55
rs6470194 734 FER1L6
rs6543342 5947 NCK2
rs679563 8828 TNFRSF9
rs682359 6498 PLA2G4F
rs6853952 926 ASB5
rs699853 1486 C1orf173
rs705958 3517 TULP4
rs7079928 14142 PCDH15
rs7121554 870,1949,1949,4769,13211 BCO2,SDHD,AP002884.3,TEX12,IL18
rs720625 1606 SLC6A20
rs666870 1701 RAB3IL1
rs1677193 12124 DENND5B
rs1654499 0 NLRP2
rs11887097 14307 SLC8A1
rs1104999 4074 ASTN2
rs12047618 12184 ADORA1
rs11008296 4594 ZNF438
rs10828678 100 ARHGAP21
rs1025466 10253 ADRA1B
rs1019947 5832 EMCN
rs10184513 3460 COL4A3
rs1003887 0,3509,8188 INSL3,B3GNT3,JAK3
rs11183620 5718 SLC38A4
rs1541046 0,4155 GBF1,PITX3
rs1519309 5866,10483 TLR3,FAM149A
rs1477113 2114 CTTNBP2
rs1368532 14932 TEX36
rs1333213 1963 NRG3
rs9903421 11035 KRT23
rs130561 6313 TIMP3
rs12624279 0 FOSL2
rs1669348 11,1277 TRNT1,CRBN
rs12739316 13598 LAMC1
rs1278312 7410 ADAM12
rs12638772 6180 ABCC5
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Table 16: The number of final selected low-frequency variants per gene for the
metabolite leucine
num.variants
gene
ABCC5 266
ADAM12 220
ADORA1 50
ADRA1B 12
AHRR 112
ALDH1A2 45
ANKRD33B 16
ARHGAP21 143
ASB5 80
ASTN2 78
ATE1 110
ATP6V1C1 8
B3GNT3 28
BCMO1 36
BCO2 108
C1orf173 240
C3orf55 14
CASP9 70
CCDC179 12
CELF4 10
CES5A 30
COL4A3 288
CPNE4 70
CRBN 56
CTTNBP2 102
DDI1 24
DDX60L 200
DENND5B 80
DERL3 40
DNAJC16 60
DNAJC17 35
DNASE1L3 140
EGLN3 8
EMCN 48
EML6 396
EPB41L4B 60
EPDR1 24
FAM149A 104
FER1L6 82
FGF12 14
FHL5 15
FLNB 826
FOSL2 27
GBF1 209
GLCCI1 30
GREB1 432
IL18 24
INSL3 12
IRF2 88
JAK3 68
JAZF1 18
KIAA1462 154
KRT23 40
LAMC1 200
LIPA 33
LMX1B 21
MAP2K6 35
MTL5 84
MYO16 30
MYT1L 162
NCK2 36
NF1 140
NLRP2 176
NMNAT3 28
NOS1AP 70
NRG3 132
NTF3 24
PCDH15 429
PDCD6 28
PDGFD 12
PHACTR2 36
PHGDH 70
PICALM 168
PITX3 22
PLA2G4F 120
POLDIP3 55
PPM1K 24
PPP1R14D 10
PRKCI 112
RAB11FIP4 70
RAB3IL1 108
REG3G 45
RIN3 20
RPA3-AS1 24
RSPO1 60
SDHD 60
SEPT9 150
SERHL2 30
SH3BGR 15
SLC26A3 66
SLC38A4 48
SLC6A1 168
SLC6A20 224
SLC8A1 99
SMARCB1 45
SRRM4 56
SUMF1 182
TARBP1 190
TBC1D14 72
TEX12 48
TEX36 44
TFF1 27
TIMP3 10
TLR3 72
TMPRSS3 81
TNFRSF9 30
TRNT1 140
TSC22D2 154
TUB 144
TULP4 69
VAX2 45
ZFYVE19 55
ZNF438 66
Total 10436
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Glossary
acidosis A metabolic state whereby the blood and tissue are acidic (.i.e, pH is less
than 7) for extended periods of time. 20
allele 12, 13, 16, 18, 22, 36, see variant
autosomal 3, 30, 32, 34, see autosome
chromosome A contiguous strand of DNA. In humans there are 23 chromosome
types and each individual inherits a version from both parents. Thus, the total
number of chromosomes posessed by an individual is 46. 3, 10, 11, 13, 30, 32
codon A three-nucleotide long unit of information within a protein coding genomic
region. Each codon translates to an amino acid residue present in the encoded
protein or the beginning or end of the coding region. 7, 15, see also transcription
dimorphism A binary difference i.e sexual dimorphism - difference between sexes.
19
diploid Diploid organism possess two sets of distinct chromosomes. That is, each
chromosome is present in two instances. 13
enzyme A protein which catalyzes chemical reactions. 16, 46
exome The total set of exon sequences. 1, 19, see also exon
exon A subsequence of the gene which is included in the final transcript RNA. 7, 9,
15, 22
gene A gene is a region encoding the amino acid sequence of a specific protein.
Typically one gene encodes one protein. 1, 20–22, 30, 32, 34–36, 39–44, 49
genome-wide association study A study where variation across the complete
genome is examined with respect the phenotype of interest. i, 15, 18, 19
haploid Possesing a single copy of each chromosome. 11, 13, see also diploid
heritability The amount of variance in the trait explained by common descent. 15
heterozygosity see heterozygote
heterozygote A term used to denote a diploid individual, who possesses two
different alleles within the same locus. That is, whose paternally inherited
allele differs from the maternally inherited. 10, see diploid, &
heterozygotic see heterozygote
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homologous recombination Homologous recombination is the molecular mecha-
nism of chromosomal recombination in meiosis. 13, see also meiosis
homozygosity 13, see homozygote
homozygote A term used to denote a diploid individual, who possesses two identical
alleles within the same locus. That is, whose paternally inherited allele is
identical to the maternally inherited. see also diploid, &
homozygotic see homozygote
intron A subsequence of the gene which is excluded in the final transcript RNA. 7,
9, 15
ketosis A metabolic state whereby a significant fraction of the body’s energy is
produced by consuming compounds called ketone bodies. These ketone bodies
are produced during fasting or other conditions of carbohydrate depletion. 20
linkage analysis Linkage analysis is an genetic association study design, which
associates traits to genotypes by analyzing pedigrees.The likely genomic location
of causal variants can be inferred using the observed distribution of traits across
the pedigree and the mixing properties of meiosis. 1, see also meiosis &
homologous recombination
locus The region where the variant site lies. This region can be for example a gene
or a subregion of a gene. 13, 16
meiosis The process of gamete (reproductive cell) generation. The process can be
summarily described as non-conservative cell division process of a diploid cell
resulting in haploid daughter cells. The ancestral chromosomes of the parent
cell undergo pairwise recombination (homologous recombination) and finally
duplication. 13
Mendelian Traits which inheritance follows the Mendelian inheritance model. 1,
13, 17, see Mendelian inheritance
metabolite A small-molecule compound (eg an amino acid,lipid,peptide). 1, 16,
18–23, 29, 30, 34, 39, 40, 43–46
metabolomic 16, 18, see metabolomics
mGWAS GWAS, where phenotypes are small-molecule concentration in a biofluid
or tissue. 19, 21, 22, 30, 35, 36, 38–42, 44, 46, 49
missense mutation A point mutation which results in a change of protein amino
acid sequence. 15, 44, see also codon
mutation An event whereby a genetic sequence is altered. 15, see also
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non-sense mutation A point mutation resulting in a premature stop-codon. see
15, 44
non-synonymous mutation A mutation leading to an change in amino acid
residue or a premature stop-codon. 22
pathway A chain of interacting molecules organizing the biological function of the
cell. For example, signalling pathways consist of protein molecules interacting
pairwisely to relay information across the cell to initiate process. Or metabolic
pathways which consist of sequence of chemical reactions resulting in a desired
product. 3, 20, 21, 44, 46
phenotype A set of individual traits which are defined or influenced by the genotype.
10, 15, 16, 18, 22, 43, 44
silent mutation A mutation substituting a codon with it’s synonym, thus leading
to no change in protein amino acid sequence. 15
single nucleotide polymorphism Single Nucleotide polymorphism; An alteration
of single base pair in the DNA sequence. 16, 21, 44
splice-site mutation Splice-site mutations refer to variants which confound the
intron-exon boundary leading to inappropriate inclusion of introns or exclusion
of exons to the transcript. 15, see splicing
splicing Splicing refers to the process of removing introns from the raw transcript
to form the final transcript. 7, 15
transcriptomic see transcriptomics
transcriptomics The study of gene expression activity in vivo. The amount of
transcription is measured per gene and treated as measure of activity for the
gene. Then, depending on the experiment, differences in activity are analyzed
with respect to other variables of interest. see also transcription
variant A specific version of a gene or a genomic region Though the term can be
used to refer to multiple types of differences (eg deletions or insertions), in the
context of this work only SNPs are considered. 1–3, 13, 15, 17, 19–23, 30, 32,
35–44, 49, 50
Acronyms
CAD coronary artery disease 13, 19
CL chromosomal linkage 13, see glossary:cl
CVD cardiovascular disease 27
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DNA deoxyribonucleic acid 3, 7
EPS extreme phenotype sampling 22
EXAC Exome aggregation consortium 30
GGM gaussian graphical machine 19
GWAS genome-wide association study 1, 16, see glossary: genome-wide association
study
H-NMR hydrogen nuclear magnetic resonance 16, 18
IEM inborn error of metabolism 1, 3, 17, 20–23, 27, 30, 32, 34–37, 39–41, 44, 46,
see glossary: inborn error of metabolism
LD linkage disequilibrium 12, 13, 21, see glossary:ld
LOF loss-of-function 1, 15, 17, 20, 22, 43, 44
MAF minor allele frequency 22, 36, see glossary: minor allele frequency
mGWAS metabolic genome-wide association study 3, see glossary: mGWAS
mQTL metabolic quantitative locus 18
mRNA messenger RNA 7, see
MS mass spectrometry 16, 18
QTL quantitative trait locus analysis 16
RNA ribonucleic acid 7
SNP single nucleotide polymorphism 15, 21, 35, see glossary: single nucleotide
polymorphism
T2D type 2 diabetes 13
